- Home
- SPRO vs VGI Comparison
SPRO vs VGI Comparison
Compare SPRO & VGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- VGI
- Stock Information
- Founded
- SPRO 2013
- VGI 2012
- Country
- SPRO United States
- VGI United States
- Employees
- SPRO N/A
- VGI N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- VGI Investment Managers
- Sector
- SPRO Health Care
- VGI Finance
- Exchange
- SPRO Nasdaq
- VGI Nasdaq
- Market Cap
- SPRO 110.9M
- VGI 89.7M
- IPO Year
- SPRO 2017
- VGI N/A
- Fundamental
- Price
- SPRO $2.13
- VGI N/A
- Analyst Decision
- SPRO Buy
- VGI
- Analyst Count
- SPRO 4
- VGI 0
- Target Price
- SPRO $5.00
- VGI N/A
- AVG Volume (30 Days)
- SPRO 308.6K
- VGI 46.0K
- Earning Date
- SPRO 11-13-2025
- VGI 01-01-0001
- Dividend Yield
- SPRO N/A
- VGI 12.66%
- EPS Growth
- SPRO N/A
- VGI N/A
- EPS
- SPRO N/A
- VGI N/A
- Revenue
- SPRO $48,576,000.00
- VGI N/A
- Revenue This Year
- SPRO N/A
- VGI N/A
- Revenue Next Year
- SPRO N/A
- VGI N/A
- P/E Ratio
- SPRO N/A
- VGI N/A
- Revenue Growth
- SPRO N/A
- VGI N/A
- 52 Week Low
- SPRO $0.51
- VGI $6.68
- 52 Week High
- SPRO $3.22
- VGI $7.99
- Technical
- Relative Strength Index (RSI)
- SPRO 60.07
- VGI 46.64
- Support Level
- SPRO $1.84
- VGI $7.92
- Resistance Level
- SPRO $2.05
- VGI $8.03
- Average True Range (ATR)
- SPRO 0.08
- VGI 0.06
- MACD
- SPRO 0.03
- VGI -0.00
- Stochastic Oscillator
- SPRO 85.71
- VGI 24.98
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.